242 related articles for article (PubMed ID: 23104988)
21. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.
Heuckmann JM; Hölzel M; Sos ML; Heynck S; Balke-Want H; Koker M; Peifer M; Weiss J; Lovly CM; Grütter C; Rauh D; Pao W; Thomas RK
Clin Cancer Res; 2011 Dec; 17(23):7394-401. PubMed ID: 21948233
[TBL] [Abstract][Full Text] [Related]
22. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K
J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625
[TBL] [Abstract][Full Text] [Related]
23. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
Katayama R; Friboulet L; Koike S; Lockerman EL; Khan TM; Gainor JF; Iafrate AJ; Takeuchi K; Taiji M; Okuno Y; Fujita N; Engelman JA; Shaw AT
Clin Cancer Res; 2014 Nov; 20(22):5686-96. PubMed ID: 25228534
[TBL] [Abstract][Full Text] [Related]
24. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.
Tucker ER; Tall JR; Danielson LS; Gowan S; Jamin Y; Robinson SP; Banerji U; Chesler L
Mol Oncol; 2017 Aug; 11(8):996-1006. PubMed ID: 28432815
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma.
Xu F; Li H; Sun Y
Biochem Biophys Res Commun; 2014 Nov; 454(4):566-71. PubMed ID: 25450694
[TBL] [Abstract][Full Text] [Related]
26. Emerging importance of ALK in neuroblastoma.
Azarova AM; Gautam G; George RE
Semin Cancer Biol; 2011 Oct; 21(4):267-75. PubMed ID: 21945349
[TBL] [Abstract][Full Text] [Related]
27. Targeted Therapy for Neuroblastoma: ALK Inhibitors.
Schulte JH; Schulte S; Heukamp LC; Astrahantseff K; Stephan H; Fischer M; Schramm A; Eggert A
Klin Padiatr; 2013 Nov; 225(6):303-8. PubMed ID: 24166094
[TBL] [Abstract][Full Text] [Related]
28. Anaplastic lymphoma kinase L1198F and G1201E mutations identified in anaplastic thyroid cancer patients are not ligand-independent.
Guan J; Wolfstetter G; Siaw J; Chand D; Hugosson F; Palmer RH; Hallberg B
Oncotarget; 2017 Feb; 8(7):11566-11578. PubMed ID: 28030793
[TBL] [Abstract][Full Text] [Related]
29. Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.
Guan J; Fransson S; Siaw JT; Treis D; Van den Eynden J; Chand D; Umapathy G; Ruuth K; Svenberg P; Wessman S; Shamikh A; Jacobsson H; Gordon L; Stenman J; Svensson PJ; Hansson M; Larsson E; Martinsson T; Palmer RH; Kogner P; Hallberg B
Cold Spring Harb Mol Case Stud; 2018 Aug; 4(4):. PubMed ID: 29907598
[TBL] [Abstract][Full Text] [Related]
30. Anaplastic lymphoma kinase (ALK) inhibitor response in neuroblastoma is highly correlated with ALK mutation status, ALK mRNA and protein levels.
Duijkers FA; Gaal J; Meijerink JP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
Cell Oncol (Dordr); 2011 Oct; 34(5):409-17. PubMed ID: 21625996
[TBL] [Abstract][Full Text] [Related]
31. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed
Liu T; Merguerian MD; Rowe SP; Pratilas CA; Chen AR; Ladle BH
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34210658
[TBL] [Abstract][Full Text] [Related]
32. Mutation-Independent Activation of the Anaplastic Lymphoma Kinase in Neuroblastoma.
Regairaz M; Munier F; Sartelet H; Castaing M; Marty V; Renauleaud C; Doux C; Delbé J; Courty J; Fabre M; Ohta S; Vielh P; Michiels S; Valteau-Couanet D; Vassal G
Am J Pathol; 2016 Feb; 186(2):435-45. PubMed ID: 26687816
[TBL] [Abstract][Full Text] [Related]
33. Identification of ALK as a major familial neuroblastoma predisposition gene.
Mossé YP; Laudenslager M; Longo L; Cole KA; Wood A; Attiyeh EF; Laquaglia MJ; Sennett R; Lynch JE; Perri P; Laureys G; Speleman F; Kim C; Hou C; Hakonarson H; Torkamani A; Schork NJ; Brodeur GM; Tonini GP; Rappaport E; Devoto M; Maris JM
Nature; 2008 Oct; 455(7215):930-5. PubMed ID: 18724359
[TBL] [Abstract][Full Text] [Related]
34. Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.
Siaw JT; Wan H; Pfeifer K; Rivera VM; Guan J; Palmer RH; Hallberg B
Oncotarget; 2016 May; 7(20):29011-22. PubMed ID: 27049722
[TBL] [Abstract][Full Text] [Related]
35. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.
Cazes A; Lopez-Delisle L; Tsarovina K; Pierre-Eugène C; De Preter K; Peuchmaur M; Nicolas A; Provost C; Louis-Brennetot C; Daveau R; Kumps C; Cascone I; Schleiermacher G; Prignon A; Speleman F; Rohrer H; Delattre O; Janoueix-Lerosey I
Oncotarget; 2014 May; 5(9):2688-702. PubMed ID: 24811913
[TBL] [Abstract][Full Text] [Related]
36. Effect of missense mutations on structure and interaction of anaplastic Lymphoma kinase (ALK) in neuroblastom.
Kanwal H; Khan MH; Rashid H
Pak J Pharm Sci; 2013 May; 26(3):611-6. PubMed ID: 23625438
[TBL] [Abstract][Full Text] [Related]
37. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen.
Zhang S; Wang F; Keats J; Zhu X; Ning Y; Wardwell SD; Moran L; Mohemmad QK; Anjum R; Wang Y; Narasimhan NI; Dalgarno D; Shakespeare WC; Miret JJ; Clackson T; Rivera VM
Chem Biol Drug Des; 2011 Dec; 78(6):999-1005. PubMed ID: 22034911
[TBL] [Abstract][Full Text] [Related]
38. Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells.
Schönherr C; Yang HL; Vigny M; Palmer RH; Hallberg B
Oncogene; 2010 May; 29(19):2817-30. PubMed ID: 20190816
[TBL] [Abstract][Full Text] [Related]
39. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.
Bagci O; Tumer S; Olgun N; Altungoz O
Cancer Lett; 2012 Apr; 317(1):72-7. PubMed ID: 22085494
[TBL] [Abstract][Full Text] [Related]
40. The neuroblastoma ALK(I1250T) mutation is a kinase-dead RTK in vitro and in vivo.
Schönherr C; Ruuth K; Eriksson T; Yamazaki Y; Ottmann C; Combaret V; Vigny M; Kamaraj S; Palmer RH; Hallberg B
Transl Oncol; 2011 Aug; 4(4):258-65. PubMed ID: 21804922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
